The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers ...

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 price ...

D. Boral Capital initiated coverage of Checkpoint Therapeutics (CKPT) with a Buy rating and $9 price target The company’s lead drug, Unloxcty, ...

Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with ...

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...

About AB-101 AB-101 is our oral PD-L1 inhibitor candidate that we believe will allow for controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint ...